Fig. 9: PD-L2 blockading therapy on colorectal cancer in LXN-deficient mice. | Cell Death Discovery

Fig. 9: PD-L2 blockading therapy on colorectal cancer in LXN-deficient mice.

From: Loss of LXN promotes macrophage M2 polarization and PD-L2 expression contributing cancer immune-escape in mice

Fig. 9

A Experimental time line for the implantation of MC38 cells in LXN KO mice and therapeutic schedule. B Cancer cell bearing mice were treated with anti-PD-L1, anti-PD-L2, anti-PD-L2/PD-L2, or IgG control. The growth of the implanted tumor size was measured every 2 days. n = 6, *P < 0.05, n.s. no significance. C Representative images of mice bearing tumor formed by MC38 cells, and quantification of tumor weight at the end point after antibody therapy. n = 6, *P < 0.05, n.s. no significance. D Representative dot plots and of quantification of CD4+ and CD8+ T cells in tumor after antibody therapy. n = 6, *P < 0.05, n.s. no significance.

Back to article page